| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| ln Vitro |
Cholesteryl oleate serves as a lipid component in cationic solid lipid nanoparticles (cSLNs) for siRNA delivery; cSLNs loaded with Cholesteryl oleate enhance cellular uptake of siRNA in HeLa cells, achieving a target gene (GFP) silencing efficiency of 78% at a siRNA concentration of 50 nM[2]
Cholesteryl oleate-containing cSLNs show low cytotoxicity in HeLa cells; after 24-hour incubation with cSLNs (final Cholesteryl oleate concentration up to 20 μg/mL), cell viability remains above 85% compared to the control group[2] |
|---|---|
| Cell Assay |
For gene silencing and cellular uptake assay: Culture HeLa cells stably expressing GFP in RPMI 1640 medium supplemented with fetal bovine serum; seed cells in 24-well plates and incubate until 70-80% confluence; treat cells with Cholesteryl oleate-containing cSLNs (formulated with siRNA at 10-50 nM) for 4 hours; replace with fresh medium and continue culturing for 20 hours; analyze GFP expression via flow cytometry to quantify silencing efficiency, and observe cellular uptake of fluorescently labeled cSLNs via confocal laser scanning microscopy[2]
For cytotoxicity assay: Seed HeLa cells in 96-well plates (5×10³ cells/well); treat cells with serial concentrations of Cholesteryl oleate-containing cSLNs (final Cholesteryl oleate concentration 5-20 μg/mL) for 24 hours; add MTT reagent and incubate for 4 hours; dissolve formazan crystals with DMSO; measure absorbance at 570 nm to evaluate cell viability[2] |
| Toxicity/Toxicokinetics |
Oleic cholesterol ester exhibits extremely low cytotoxicity in vitro; when incorporated into cSLN, it does not induce significant HeLa cell death at effective gene silencing concentrations (≤20 μg/mL)[2].
|
| References |
|
| Additional Infomation |
Oleic cholesterol ester is the (Z)-stereomer of octadec-9-enoic acid cholesterol ester. It is a mouse metabolite. It is an octadec-9-enoic acid cholesterol ester and also a CE (18:1). It is functionally related to oleic acid. Oleic cholesterol ester has been reported to have been found in Homo sapiens and there is relevant data. Oleic cholesterol ester exhibits good miscibility in ceramide-cholesterol-fatty acid matrix; when the mass fraction of oleic cholesterol ester is 0.1-0.3, it forms a homogeneous mixture with the matrix, and no phase separation is observed by differential scanning calorimetry and X-ray diffraction [1].
The miscibility of oleic cholesterol esters in lipid matrices is affected by the chain length of fatty acids; fatty acids containing 16-18 carbon atoms can achieve the best miscibility[1] Oleic cholesterol is a key lipid component of cationic solid lipid nanoparticles, which helps to stabilize the nanoparticle structure and improve the encapsulation efficiency and intracellular delivery of siRNA[2] |
| Molecular Formula |
C45H78O2
|
|---|---|
| Molecular Weight |
651.09962
|
| Exact Mass |
650.6
|
| CAS # |
303-43-5
|
| Related CAS # |
Cholesteryl oleate-d7;1416275-35-8;Cholesteryl oleate-d7-1;2260669-48-3
|
| PubChem CID |
5283632
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
675.4±44.0 °C at 760 mmHg
|
| Melting Point |
44-47 °C(lit.)
|
| Flash Point |
362.9±16.0 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.511
|
| LogP |
18.69
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
47
|
| Complexity |
977
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
RJECHNNFRHZQKU-RMUVNZEASA-N
|
| InChi Code |
InChI=1S/C45H78O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-25-43(46)47-38-30-32-44(5)37(34-38)26-27-39-41-29-28-40(36(4)24-22-23-35(2)3)45(41,6)33-31-42(39)44/h14-15,26,35-36,38-42H,7-13,16-25,27-34H2,1-6H3/b15-14-/t36-,38+,39+,40-,41+,42+,44+,45-/m1/s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (Z)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Acetone : 50 mg/mL (~76.79 mM)
Ethanol : ~12.5 mg/mL (~19.20 mM ) DMSO :< 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (1.92 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.25 mg/mL (1.92 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (1.92 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 0.52 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.2 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 0.52 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.2 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 0.52 mg/mL (0.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.2 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5359 mL | 7.6793 mL | 15.3586 mL | |
| 5 mM | 0.3072 mL | 1.5359 mL | 3.0717 mL | |
| 10 mM | 0.1536 mL | 0.7679 mL | 1.5359 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
